---
title: "Shenzhen Hepalink Pharmaceutical Group Co.,Ltd. (002399.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002399.SZ.md"
symbol: "002399.SZ"
name: "Shenzhen Hepalink Pharmaceutical Group Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-03-03T13:18:45.301Z"
locales:
  - [en](https://longbridge.com/en/quote/002399.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002399.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002399.SZ.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/002399.SZ.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002399.SZ.md)


# Shenzhen Hepalink Pharmaceutical Group Co.,Ltd. (002399.SZ)

## Company Overview

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products, such as prolongin, inhixa, neoparin, and heparin and enoxaparin sodium injections; API products, including heparin and enoxaparin sodium APIs; and pancreatin API.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.hepalink.com](https://www.hepalink.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-03T04:30:10.000Z

**Overall: C (0.47)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 89 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.96% |  |
| Net Profit YoY | 387.19% |  |
| P/B Ratio | 1.40 |  |
| Dividend Ratio | 2.12% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 17332781362.04 |  |
| Revenue | 5404009510.35 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.43% | C |
| Profit Margin | 7.80% | B |
| Gross Margin | 35.79% | C |
| Revenue YoY | -0.96% | D |
| Net Profit YoY | 387.19% | A |
| Total Assets YoY | -5.48% | D |
| Net Assets YoY | 1.73% | C |
| Cash Flow Margin | 1281.39% | B |
| OCF YoY | -0.96% | D |
| Turnover | 0.31 | D |
| Gearing Ratio | 27.46% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.96%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "387.19%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.40",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.12%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "17332781362.04",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5404009510.35",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.43%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "7.80%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "35.79%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-0.96%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "387.19%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-5.48%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.73%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "1281.39%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-0.96%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.31",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.46%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 40.68 | 99/222 | 43.19 | 41.10 | 26.41 |
| PB | 1.38 | 22/222 | 1.49 | 1.43 | 1.37 |
| PS (TTM) | 3.16 | 75/222 | 3.42 | 3.29 | 3.14 |
| Dividend Yield | 2.15% | 50/222 | 2.10% | 2.06% | 1.94% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | B | B | A |
| 02 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 03 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 04 | Salubris (002294.SZ) | B | B | C | A | B | B |
| 05 | Haisco (002653.SZ) | B | C | B | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-02T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Sell | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.65 |
| Highest Target | 8.60 |
| Lowest Target | 8.60 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002399.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002399.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002399.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002399.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**